These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32634290)

  • 21. Rhenium-Based Complexes and in Vivo Testing: A Brief History.
    Capper MS; Packman H; Rehkämper M
    Chembiochem; 2020 Aug; 21(15):2111-2115. PubMed ID: 32196894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy.
    Zheng K; Wu Q; Wang C; Tan W; Mei W
    Anticancer Agents Med Chem; 2017; 17(1):29-39. PubMed ID: 27349451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deferasirox protects against hydrogen peroxide-induced cell apoptosis by inhibiting ubiquitination and degradation of p21
    Miao J; Xu M; Kuang Y; Pan S; Hou J; Cao P; Duan X; Chang Y; Hasem H; Zhou N; Tan K; Fan Y
    Biochem Biophys Res Commun; 2020 Apr; 524(3):736-743. PubMed ID: 32035614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
    Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
    Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclometalated iridium(iii) complexes induce mitochondria-derived paraptotic cell death and inhibit tumor growth in vivo.
    He L; Wang KN; Zheng Y; Cao JJ; Zhang MF; Tan CP; Ji LN; Mao ZW
    Dalton Trans; 2018 May; 47(20):6942-6953. PubMed ID: 29721561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pt(IV)-Deferasirox Prodrug Combats DNA Damage Repair by Regulating RNA N
    Pan ZY; Ling YY; Zhang H; Hao L; Tan CP; Mao ZW
    J Med Chem; 2022 Nov; 65(21):14692-14700. PubMed ID: 36353870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An "Iron-phagy" nanoparticle inducing irreversible mitochondrial damages for antitumor therapy.
    Wang Z; Xiang S; Qiu Y; Yu F; Li S; Zhang S; Song G; Xu Y; Meng T; Yuan H; Hu F
    J Control Release; 2024 Oct; 374():400-414. PubMed ID: 39153721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinatorial Synthesis to Identify a Potent, Necrosis-Inducing Rhenium Anticancer Agent.
    Konkankit CC; Vaughn BA; MacMillan SN; Boros E; Wilson JJ
    Inorg Chem; 2019 Mar; 58(6):3895-3909. PubMed ID: 30793900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
    Chang YC; Lo WJ; Huang YT; Lin CL; Feng CC; Lin HT; Cheng HC; Yeh SP
    Leuk Lymphoma; 2017 Sep; 58(9):1-12. PubMed ID: 28140713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron Metabolism in Cancer.
    Wang Y; Yu L; Ding J; Chen Y
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30591630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
    Salehi S; Saljooghi ASh; Shiri A
    Eur J Pharmacol; 2016 Jun; 781():209-17. PubMed ID: 27090924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coumarin-appended phosphorescent cyclometalated iridium(iii) complexes as mitochondria-targeted theranostic anticancer agents.
    Ye RR; Tan CP; Ji LN; Mao ZW
    Dalton Trans; 2016 Aug; 45(33):13042-51. PubMed ID: 27139504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mixed-ligand ruthenium polypyridyl complexes as apoptosis inducers in cancer cells, the cellular translocation and the important role of ROS-mediated signaling.
    Zhao Z; Luo Z; Wu Q; Zheng W; Feng Y; Chen T
    Dalton Trans; 2014 Dec; 43(45):17017-28. PubMed ID: 25087850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondria targeted and NADH triggered photodynamic activity of chloromethyl modified Ru(ii) complexes under hypoxic conditions.
    Tian N; Sun W; Guo X; Lu J; Li C; Hou Y; Wang X; Zhou Q
    Chem Commun (Camb); 2019 Feb; 55(18):2676-2679. PubMed ID: 30747181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design of Rhenium Compounds in Targeted Anticancer Therapeutics.
    Collery P; Desmaele D; Vijaykumar V
    Curr Pharm Des; 2019; 25(31):3306-3322. PubMed ID: 31475892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Photoinduced anticancer activity studies of iridium(III) complexes targeting mitochondria and tubules.
    Zhang WY; Yi QY; Wang YJ; Du F; He M; Tang B; Wan D; Liu YJ; Huang HL
    Eur J Med Chem; 2018 May; 151():568-584. PubMed ID: 29656200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats.
    Rahdar A; Hajinezhad MR; Sargazi S; Bilal M; Barani M; Karimi P; Kyzas GZ
    Life Sci; 2021 Apr; 270():119146. PubMed ID: 33545199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneously Inducing and Tracking Cancer Cell Metabolism Repression by Mitochondria-Immobilized Rhenium(I) Complex.
    Yang J; Zhao JX; Cao Q; Hao L; Zhou D; Gan Z; Ji LN; Mao ZW
    ACS Appl Mater Interfaces; 2017 Apr; 9(16):13900-13912. PubMed ID: 28368110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, Structure Characterization and Antitumor Activity Study of a New Iron(III) Complex of 5-Nitro-8-hydroxylquinoline (HNOQ).
    Zhang HR; Meng T; Liu YC; Qin QP; Chen ZF; Liu YN; Liang H
    Chem Pharm Bull (Tokyo); 2016 Aug; 64(8):1208-17. PubMed ID: 27238362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers.
    Collery P; Veena V; Harikrishnan A; Desmaele D
    Invest New Drugs; 2019 Oct; 37(5):973-983. PubMed ID: 30632005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.